Polio eradication in India: Progress, but environmental surveillance and vigilance still needed

Vaccine

Volumn 31, Issue 9, 2013, Pages 1268-1275

  Chatterjee, Animesh ^a   Vidyant, Sanjukta ^a   Dhole, Tapan N ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Epidemiology; Polio; Polio vaccine virus; Public health; Surveillance

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

DISEASE SURVEILLANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; IMMUNIZATION; INDIA; MOLECULAR EPIDEMIOLOGY; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW;

DISEASE ERADICATION; EPIDEMIOLOGICAL MONITORING; HUMANS; INDIA; POLIOMYELITIS; POLIOVIRUS VACCINES;

EID: 84873424816     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.060     Document Type: Review

References (56)

1. Andrus J.K., Thapa A.B., Withana N., Fitzsimmons J.W., Abeykoon P., Aylward B. A new paradigm for international disease control: lessons learned from polio eradication in Southeast Asia. Am J Public Health 2001, 91:146-150.
2. Alexander L.N., Seward J.F., Santibanez T.A., Pallansch M.A., Kew O.M., Prevots D.R., et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. J Am Med Assoc 2004, 292:1696-1701.
3. Barrett S. Polio eradication: strengthening the weakest links. Health Aff (Millwood) 2009, 28:1079-1090.
4. Blomqvist S., Savolainen C., Laine P., Hirttio P., Lamminsalo E., Pentilla E., et al. Characterisation of a highly evolved vaccine derived poliovirus type 3 isolated from sewage in Estonia. J Virol 2004, 78:4876-4883.
5. Blume S., Geesink I. A brief history of polio vaccines. Science 2000, 288:1593-1594.
6. Blume S.S. Lock in, the state and vaccine development: lessons from the history of the polio vaccines. Res Policy 2005, 34:159-173.
7. Buttinelli G., Donati V., Fiore S., Marturano J., Plebani A., Balestri P., et al. Nucleotide variation in sabin type 2 poliovirus from an immunodeficient patient with poliomyletis. J Gen Virol 2003, 84:1215-1221.
8. Centers for Disease Control and Prevention Circulation of a type 2 vaccine-derived poliovirus-Egypt, 1982-1993. Morb Mortal Wkly Rep 2001, 50. 41-2, 51.
9. Centers for Disease Control and Prevention Progress towards global eradication of poliomyletis, 2001. Morb Mortal Wkly Rep 2002, 51:253-256.
10. Centers for Disease Control and Prevention Update on vaccine-derived polioviruses-worldwide, January 2008-June 2009. Morb Mortal Wkly Rep 2009, 58:1002-1006.
11. Centers for Disease control and Prevention Progress toward poliomyelitis eradication-India, January 2009-October 2010. Morb Mortal Wkly Rep 2010, 59:1581-1585.
12. Centers for Disease Control and Prevention Update on vaccine-derived polioviruses-worldwide, July 2009-June 2011. Morb Mortal Wkly Rep 2011, 60:846-850.
13. Centers for Disease Control and Prevention Update on vaccine-derived polioviruses-worldwide, April 2011-June 2012. Morb Mortal Wkly Rep 2012, 61:741-746.
14. Dömök I. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982. Rev Infect Dis 1984, 6:S413-S418.
15. Divizia M., Palombi L., Buonomo E., Donia D., Ruscio V., Equestre M., et al. Genomic characterization of human and environmental polioviruses isolated in Albania. Appl Environ Microbiol 1999, 65:3534-3539.
16. Dove A. Paralytic poliomyletis returns to the Western Hemisphere. PICO News: Caribbean Outbreak; 2001.
17. Estívariz C.F., Molnár Z., Venczel L., Kapusinszky B., Zingeser J.A., Lipskaya G.Y., et al. Paralytic poliomyelitis associated with sabin monovalent and bivalent oral polio vaccines in Hungary. Am J Epidemiol 2011, 174:316-325.
18. Friedrich F. Genomic modifications in oral poliovirus vaccine strains after multiplication in humans and implications for the eradication of poliovirus. Acta Virol 2000, 44:109-117.
19. Ghendon Y., Robertson S.E. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Org 1994, 72:973-983.
20. Grassly N.C., Wenger J., Durrani S., Bahl S., Deshpande J.M., Sutter R.W., et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 2007, 369:1356-1362.
21. Grassly N.C., Jafari H., Bahl S., Durrani S., Wenger J., Sutter R.W., et al. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis 2009, 200:794-801.
22. Heymann D.L., Sutter R.W., Aylward R.B. A vision of a world without polio: the OPV cessation strategy. Biologicals 2006, 34(2):75-79.
23. Heymann D.L., Sutter R.W., Aylward R.B. Polio eradication: interrupting transmission, towards a polio-free world. Future Virol 2006, 1:181-188.
24. Horie H., Yoshida H., Matsuura K., Miyazawa M., Wakabayashi K., Nomoto A., et al. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. J Med Virol 2002, 68:445-451.
25. Jenkins H.E., Aylward R.B., Gasasira A., Donnelly C.A., Mwanza M., Corander J., et al. Implication of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med 2010, 362:2360-2369.
26. John T.J., Jain H., Ravishankar K., Amaresh A., Verma H., Deshpande J., et al. Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials. Vaccine 2011, 29:5793-5801.
27. Kaura G., Abraham T. Polio eradication: a complex end game. BMJ 2012, 344:e2398.
28. Kew O.M., Sutter R.W., Nottay B.K., McDonough M.J., Prevots D.R., Quick L., et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 1998, 36:2893-2899.
29. Kew O.M., Wright P.F., Agol V.I. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Org 2004, 82:16-23.
30. Lasch E.E., Abed Y., Marcus O., Gerichter C.B., Melnick J.L. Combined live and inactivated poliovirus vaccine to control poliomyelitis in a developing country - five years after. Dev Biol Stand 1986, 65:43-137.
31. Martin J., Ferguson G.L., Wood D.J., Minor P.D. The vaccine origin of the 1968 epidemic of type 3 poliomyletis in Poland. Virology 2000, 278:42-49.
32. Martin J. Detection and characterization of polioviruses. Methods Mol Biol (Cliffton) 2011, 665:233.
33. Modlin J.F. The bumpy road to polio eradication. N Engl J Med 2010, 362:2346-2349.
34. Mukherji W.C.S., Jindal L.C.A.K., Singh B.Z. Polio eradication in India: myth or reality. Med J Arm Forces India 2005, 61:364-366.
35. Kew O. Reaching the last one per cent: progress and challenges in global polio eradication. Curr Opin Virol 2012, 2:188-198.
36. Paul Y. Role of genetic factors in polio eradication: new challenge for policy makers. Vaccine 2007, 25:8365-8371.
37. Pelczar M.J., Chan E.C.S., Krieg N.R. Microbiology: concepts and applications 1993, McGraw-Hill, Inc., New Delhi, India, p. 698.
38. Rousset D., Rakoto-Andrianarivelo M., Razafindratsimandresy R., Randriamanalina B., Guillot S., Balanant J., et al. Recombinant vaccine-derived poliovirus in Madagascar. Emerg Infect Dis 2003, 9:885-887.
39. Sathyamala C., Mittal O., Dasgupta R., Priya R. Polio eradication initiative in India: deconstructing the GPEI. Int J Health Serv 2005, 35:361-383.
40. Shulman L.M., Manor J., Handsher R., Delpeyroux F., MacDonough M.J., Halmut T., et al. Molecular and antigenic characterisation of a highly evolved derivative of the type 2 oral polio vaccine strain isolated from sewage in Israel. J Clin Microbiol 2000, 38:3729-3734.
41. Sutter R.W., Patriarca P.A. Inactivated and live, attenuated poliovirus vaccines: mucosal immunity. Measles and poliomyelitis - vaccines and immunization 1993, 279-294. Springer, New York, NY. E. Kurstak (Ed.).
42. Sutter R.W., Prevots D.R. Vaccine-associated paralytic poliomyletis among immunodeficient persons. Infect Med 1994, 11:426-438.
43. Sutter R.W., Tangermann R.H., Aylward R.B., Cochi S.L. Poliomyelitis eradication: progress, challenges for the end game, and preparation for the post-eradication era. Infect Dis Clin North Am 2001, 15:41-64.
44. Von Magnus H., Petersen I. Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 1984, 6:S471-S474.
45. Vashishtha V.M. Polio eradication in India: need for caution. Indian J Pediatr 2009, 76:757.
46. Wood D.J., Sutter R.W., Dowdle W.R. Stopping poliovirus vaccination after eradication: issues and challenges. Bull World Health Org 2000, 78:347-357.
47. Wood N., Thorley B. Viewpoint towards global poliomyletis eradication: the successes and challenges for a developed country. J Paediatr Child Health 2003, 39:647-650.
48. World Health and Organization Outbreak news. Wkly Epidemiol Rec 2000, 75:397-399.
49. World Health Organization Manual for the virological investigation of poliomyletis 2002, World Health Organization, Geneva, Switzerland, [WHO/EPI/GEN/02.1].
50. World Health Organization OPV virus circulation and evolution investigated in NewZealand. Polio Laboratory Network Quaterly Update 2003, 9:2-3.
51. World Health Organization Progress towards the global eradication of poliomyletis, 2002. Wkly Epidemiol Rec 2003, 78:138-144.
52. World Health Organization Manual for the virological investigation of poliomyletis 2004, World Health Organization, Geneva, Switzerland, [WHO/EPI/GEN/04].
53. World Health Organization Meeting of the Strategic Advisory Group of Experts on immunization, April 2012 - conclusions and recommendations. Wkly Epidemiol Rec 2012, 87:201-216.
54. Yang C.F., Naguib T., Yang S.J., Nasr E., Jorba J., Ahmed N., et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983-1993. J Virol 2003, 77:8366-8377.
55. Yoshida H., Horie H., Matsuura K., Kitamura T., Hashizumi S., Miyamura T. Prevalence of vaccine-derived polioviruses in the environment. J Gen Virol 2002, 83:1107-1111.
56. Zaoutis T., Klein J.D. Enterovirus infections. Pediatr Rev 1998, 19:183-191.